These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

328 related items for PubMed ID: 32229099

  • 1. Ribociclib mitigates cisplatin-associated kidney injury through retinoblastoma-1 dependent mechanisms.
    Kim JY, Jayne LA, Bai Y, Feng MJHH, Clark MA, Chung S, W Christman J, Cianciolo RE, Pabla NS.
    Biochem Pharmacol; 2020 Jul; 177():113939. PubMed ID: 32229099
    [Abstract] [Full Text] [Related]

  • 2. Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions.
    Pabla N, Gibson AA, Buege M, Ong SS, Li L, Hu S, Du G, Sprowl JA, Vasilyeva A, Janke LJ, Schlatter E, Chen T, Ciarimboli G, Sparreboom A.
    Proc Natl Acad Sci U S A; 2015 Apr 21; 112(16):5231-6. PubMed ID: 25848011
    [Abstract] [Full Text] [Related]

  • 3. Ribociclib (LEE011) suppresses cell proliferation and induces apoptosis of MDA-MB-231 by inhibiting CDK4/6-cyclin D-Rb-E2F pathway.
    Li T, Xiong Y, Wang Q, Chen F, Zeng Y, Yu X, Wang Y, Zhou F, Zhou Y.
    Artif Cells Nanomed Biotechnol; 2019 Dec 21; 47(1):4001-4011. PubMed ID: 31588803
    [Abstract] [Full Text] [Related]

  • 4. CDK4/6 inhibition induces epithelial cell cycle arrest and ameliorates acute kidney injury.
    DiRocco DP, Bisi J, Roberts P, Strum J, Wong KK, Sharpless N, Humphreys BD.
    Am J Physiol Renal Physiol; 2014 Feb 15; 306(4):F379-88. PubMed ID: 24338822
    [Abstract] [Full Text] [Related]

  • 5. Ribociclib, a selective cyclin D kinase 4/6 inhibitor, inhibits proliferation and induces apoptosis of human cervical cancer in vitro and in vivo.
    Xiong Y, Li T, Assani G, Ling H, Zhou Q, Zeng Y, Zhou F, Zhou Y.
    Biomed Pharmacother; 2019 Apr 15; 112():108602. PubMed ID: 30784916
    [Abstract] [Full Text] [Related]

  • 6. Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells.
    Reiter FP, Denk G, Ziesch A, Ofner A, Wimmer R, Hohenester S, Schiergens TS, Spampatti M, Ye L, Itzel T, Munker S, Teufel A, Gerbes AL, Mayerle J, De Toni EN.
    Cell Oncol (Dordr); 2019 Oct 15; 42(5):705-715. PubMed ID: 31250364
    [Abstract] [Full Text] [Related]

  • 7. Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation.
    Bonelli M, La Monica S, Fumarola C, Alfieri R.
    Biochem Pharmacol; 2019 Dec 15; 170():113676. PubMed ID: 31647925
    [Abstract] [Full Text] [Related]

  • 8. Ribociclib, a Cdk4/Cdk6 kinase inhibitor, enhances glucocorticoid sensitivity in B-acute lymphoblastic leukemia (B-All).
    Bortolozzi R, Mattiuzzo E, Trentin L, Accordi B, Basso G, Viola G.
    Biochem Pharmacol; 2018 Jul 15; 153():230-241. PubMed ID: 29408328
    [Abstract] [Full Text] [Related]

  • 9. Combining CDK4/6 inhibitors ribociclib and palbociclib with cytotoxic agents does not enhance cytotoxicity.
    Jin D, Tran N, Thomas N, Tran DD.
    PLoS One; 2019 Jul 15; 14(10):e0223555. PubMed ID: 31600301
    [Abstract] [Full Text] [Related]

  • 10. PROTACs suppression of CDK4/6, crucial kinases for cell cycle regulation in cancer.
    Zhao B, Burgess K.
    Chem Commun (Camb); 2019 Feb 26; 55(18):2704-2707. PubMed ID: 30758029
    [Abstract] [Full Text] [Related]

  • 11. Downregulation of PARP1 transcription by CDK4/6 inhibitors sensitizes human lung cancer cells to anticancer drug-induced death by impairing OGG1-dependent base excision repair.
    Tempka D, Tokarz P, Chmielewska K, Kluska M, Pietrzak J, Rygielska Ż, Virág L, Robaszkiewicz A.
    Redox Biol; 2018 May 26; 15():316-326. PubMed ID: 29306194
    [Abstract] [Full Text] [Related]

  • 12. CDK4/6 inhibition presents as a therapeutic option for paediatric and adult germ cell tumours and induces cell cycle arrest and apoptosis via canonical and non-canonical mechanisms.
    Skowron MA, Vermeulen M, Winkelhausen A, Becker TK, Bremmer F, Petzsch P, Schönberger S, Calaminus G, Köhrer K, Albers P, Nettersheim D.
    Br J Cancer; 2020 Aug 26; 123(3):378-391. PubMed ID: 32418994
    [Abstract] [Full Text] [Related]

  • 13. Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors.
    Tripathy D, Bardia A, Sellers WR.
    Clin Cancer Res; 2017 Jul 01; 23(13):3251-3262. PubMed ID: 28351928
    [Abstract] [Full Text] [Related]

  • 14. [Protective effect and mechanism of Ribociclib on sepsis induced-acute kidney injury].
    Wang Q, Gong X, Jia J, Li G.
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Feb 01; 32(2):204-209. PubMed ID: 32275007
    [Abstract] [Full Text] [Related]

  • 15. RABL6A Is an Essential Driver of MPNSTs that Negatively Regulates the RB1 Pathway and Sensitizes Tumor Cells to CDK4/6 Inhibitors.
    Kohlmeyer JL, Kaemmer CA, Pulliam C, Maharjan CK, Samayoa AM, Major HJ, Cornick KE, Knepper-Adrian V, Khanna R, Sieren JC, Leidinger MR, Meyerholz DK, Zamba KD, Weimer JM, Dodd RD, Darbro BW, Tanas MR, Quelle DE.
    Clin Cancer Res; 2020 Jun 15; 26(12):2997-3011. PubMed ID: 32086342
    [Abstract] [Full Text] [Related]

  • 16. A selective cyclin-dependent kinase 4, 6 dual inhibitor, Ribociclib (LEE011) inhibits cell proliferation and induces apoptosis in aggressive thyroid cancer.
    Lee HJ, Lee WK, Kang CW, Ku CR, Cho YH, Lee EJ.
    Cancer Lett; 2018 Mar 28; 417():131-140. PubMed ID: 29306020
    [Abstract] [Full Text] [Related]

  • 17. Preclinical Activity of Ribociclib in Squamous Cell Carcinoma of the Head and Neck.
    van Caloen G, Schmitz S, El Baroudi M, Caignet X, Pyr Dit Ruys S, Roger PP, Vertommen D, Machiels JP.
    Mol Cancer Ther; 2020 Mar 28; 19(3):777-789. PubMed ID: 31924739
    [Abstract] [Full Text] [Related]

  • 18. [Targeting the cyclin-dependent kinases 4/6 in advanced breast cancers].
    Coussy F, Deluche E, Pistilli B, Ladoire S, Ferrero JM, Cottu P.
    Bull Cancer; 2021 Sep 28; 108(9):843-854. PubMed ID: 34154797
    [Abstract] [Full Text] [Related]

  • 19. Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.
    Scott SC, Lee SS, Abraham J.
    Semin Oncol; 2017 Dec 28; 44(6):385-394. PubMed ID: 29935900
    [Abstract] [Full Text] [Related]

  • 20. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
    Spring LM, Zangardi ML, Moy B, Bardia A.
    Oncologist; 2017 Sep 28; 22(9):1039-1048. PubMed ID: 28706010
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.